Higher insurance co-pays reduce treatment compliance in women with breast cancer

Higher insurance co-pays reduce treatment compliance in women with breast cancer

A study presented at an American Association of Cancer Research (AACR) conference demonstrated that women are less likely to adhere to their treatment if they have higher co-pays. The study examined women taking aromatase inhibitors for breast cancer.  They found that if the co-pays were higher, women were more likely to stop taking the medication.  This was especially true for elderly women.